Targeting the Mevalonate Pathway for Treating Lung Cancer

The mevalonate (MVA) pathway is a key metabolic pathway involved in various important cellular functions. Its downstream products are critical for cell-signaling, cell membrane integrity, protein synthesis, and cellular respiration. The rate-limiting enzyme of this pathway is targeted by statins, a class of medications best known for their lipid-lowering effects. Many studies have shown that a variety of cancerous cells have a dysregulated MVA pathway. Lung cancer is responsible for a third of all cancer-related deaths worldwide. As our understanding of the molecular mechanisms driving the pathogenesis of lung cancer improves, newer therapeutics have been proposed. However, these medications have not had the expected benefits for all subtypes of lung cancer. Therefore, there exists a significant role in identifying medications with safe profiles, which can potentially be used in managing various types of lung cancer. Herein, we review whether there is a role in utilizing statins to target the MVA pathway in treating lung cancer.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Article Source Type: research